Rubius Therapeutics to Present at Jefferies Virtual 2020 Healthcare Conference
May 26 2020 - 4:01PM
Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage
biopharmaceutical company that is genetically engineering red blood
cells to create an entirely new class of cellular medicines, today
announced that Pablo J. Cagnoni, M.D., chief executive officer,
will participate in a fireside chat at the Jefferies Virtual 2020
Healthcare Conference on Tuesday, June 2, 2020, at 1:00 p.m. ET.
A live audio webcast will be available on the Events and
Presentations page within the Investors and Media section of the
Rubius Therapeutics website. An archived replay will be accessible
for 90 days following the event.
About Rubius Therapeutics
Rubius Therapeutics is a clinical-stage biopharmaceutical
company developing a new class of medicines called Red Cell
Therapeutics™. The Company’s proprietary RED PLATFORM® was
designed to genetically engineer and culture Red Cell Therapeutics™
that are selective, potent and off-the-shelf allogeneic cellular
therapies for the potential treatment of several diseases across
multiple therapeutic areas. Rubius’ initial focus is to advance
RCT™ product candidates for the treatment of cancer and autoimmune
diseases by leveraging two distinct therapeutic modalities — potent
cell-cell interaction and tolerance induction. For more
information, visit www.rubiustx.com, follow us on Twitter or
LinkedIn or like us on Facebook.
Contacts:
Lori Melançon Vice President, Corporate Affairs +1 (617)
949-5296 lori.melancon@rubiustx.com
Media Contact: Dan Budwick 1AB +1 (973)
271-6085 dan@1abmedia.com
Rubius Therapeutics (NASDAQ:RUBY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Rubius Therapeutics (NASDAQ:RUBY)
Historical Stock Chart
From Sep 2023 to Sep 2024